ContactContact 
Des avancées qui changent 
la vie des patients

Chez Pfizer, entreprise biopharmaceutique parmi les leaders mondiaux, nous nous appuyons sur la science, l’innovation et l’excellence technologique pour faire reculer la maladie, en offrant des médicaments et vaccins qui prolongent et améliorent considérablement la vie du plus grand nombre.

Découvrir Pfizer

La Fabrique de l'innovation en Santé

Plongez dans l’univers fascinant de l’innovation médicale. Un podcast qui vous emmène dans les coulisses d’un laboratoire pionner qui a marqué la santé mondiale, et dans lequel scientifiques et experts partagent leurs expériences, défis et succès.

En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Pfizer et WILCO lancent l’appel à candidatures de la 5ᵉ édition du Pfizer Healthcare Hub France

Le Pfizer Healthcare Hub France revient ! C’est l’heure de recruter la nouvelle promo d’entrepreneurs.

En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

L'oncologie à l'ère du numérique : quelles solutions pour les patients ?

Dans le monde, 20 millions de personnes sont atteintes d’un cancer. 

En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

S’adapter à l’évolution épidémiologique : un défi pour la vaccination

Depuis des siècles, la vaccination a permis de transformer la santé publique en réduisant drastiquement l’impact des maladies infectieuses

En savoir plus

Retour en images sur la 17e édition du Forum Patient Pfizer

Un événement attendu, qui a rassemblé cette année près de 300 participants en présentiel et en distanciel. 

En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

IA en santé : la participation des patients, un facteur clé de son succès

Le Cercle P appelle les décideurs et acteurs de la santé à penser la place des patients dans le développement des IA qui leur sont destinées.

En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Le Fonds de dotation Pfizer Innovation France et la Fondation pour la Recherche et l’Innovation en Pharmacie Hospitalière lancent un Prix


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Bien vieillir avec une maladie chronique : l’exemple du cancer métastatique

Reda Guiha, président de Pfizer France, partage sa vision pour bien vivre et vieillir en cas de cancer métastatique. 


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Podcast de Delphine Remy : regard croisé sur les cancers féminins et masculins

Hommes, femmes : sommes-nous si différents face au cancer ?  


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Prix Patient Pfizer

Le Prix Patient Pfizer est devenu une initiative phare pour soutenir les projets innovants et à fort impact pour les communautés de patients en France.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

LaVieAutour.fr

Le site qui facilite l’accès à des soins de support en oncologie près de chez soi.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Pfizer a fourni un milliard de doses de vaccin conjugué contre le pneumocoque

Pour la protection des enfants dans les pays à faibles revenus, dans le cadre de GAVI, l’alliance du vaccin.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Fin du Pfizer Healthcare Hub France Saison 4 

Le 14 novembre, venez célébrer l'innovation en santé en participant à la Demo Night, la soirée de clôture de la 4ème édition du Pfizer Healthcare Hub France.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Golden Tickets Pfizer X BioLabs France

L’appel à candidatures est ouvert pour la seconde campagne de Golden Tickets Pfizer X BioLabs. À la clé : 1 an de résidence au BioLabs Hôtel-Dieu à Paris.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Pfizer et Evotec collaborent pour faire progresser la recherche en France.

La collaboration pluriannuelle sera initialement axée sur la recherche précoce dans le champ des maladies métaboliques et infectieuses.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Comment concilier cancer du sein métastatique et vie professionnelle ?

Les traitements des cancers du sein métastatiques peuvent aider les femmes atteintes à conserver une qualité de vie leur permettant de travailler, mais l’impact de la maladie sur la vie professionnelle est important.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Choose France

Pfizer engage 500 millions d’euros pour soutenir la recherche et l’innovation en santé.  Les investissements visent à renforcer l’écosystème de la recherche et développement (R&D) en France


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Le Choix de la Science

Un e-colloque organisé avec un comité scientifique, pour échanger et confronter les points de vue sur l’impact des innovations médicales, l’économie et la société.


Voir le replay DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

La médiation transculturelle, pour rapprocher diversité et soins.

Découvrir comment l’approche transculturelle respecte les spécificités culturelles du patient dans les relations médecin-malade.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Prevent2Care, l'innovation en prévention santé. 

Découvrir le programme d'accompagnement de start-ups et d'associations françaises ayant pour objectif de favoriser l'innovation en prévention santé en France.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Prevent2Care #6 : L’appel à projets est ouvert

Chaque année en France, le potentiel de sauver 100 000 vies est entravé par le manque de développement dans le domaine de la prévention santé. Il est grand temps d'agir. 


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

« Race against resistance » :  un film pour mobiliser sur la lutte contre l’antibiorésistance

Un film titré « Race against Resistance » met en lumière le défi majeur que représente la lutte contre l’antibiorésistance pour la santé mondiale


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Pfizer et WILCO dévoilent les 5 nouvelles startups lauréates du Pfizer Healthcare Hub France

La 4ème édition du Pfizer Healthcare Hub France capitalise sur le modèle exclusif qui a fait le succès de ses précédentes éditions.


En savoir plus DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments. DISCLOSURE NOTICE: The information contained in this release is as of June 23, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about talazoparib, including its potential benefits and a potential indication in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies.

Whether and when applications for talazoparib may be filed in any jurisdictions for the potential indication or for any other indications; whether and when any such applications for talazoparib that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether talazoparib will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of talazoparib; uncertainties regarding the impact of COVID-19 of our business, operations and financial results; and competitive developments.

Reda Guiha, nouveau président de Pfizer France

Cette nomination s’inscrit dans la dynamique de transformation de Pfizer en tant qu'acteur biopharmaceutique recentré sur l'innovation, et initiée il y a quelques années déjà.


En savoir plus

Pfizer célèbre la Science dans sa nouvelle campagne

Luca Mollo, vice-président et directeur médical de Pfizer, revient sur les raisons d'une telle confiance dans la Science.


En savoir plus

La Science vaincra

Depuis la création de Pfizer en 1849, nous nous sommes appuyés sur la science pour faire reculer ou vaincre la maladie.


En savoir plus

Pfizer et WILCO lancent la 4ème édition du Pfizer Healthcare Hub France

L’appel à candidatures est ouvert aux startups françaises innovantes en santé du 5 au 29 septembre 2023.


En savoir plus

Notre modèle de l’open innovation, en France, au service des patients !

Une seule stratégie : créer des alliances à impact.


En savoir plus

La diversité ethnique et les essais cliniques, où en est-on ?

Le sexe, l’âge et l’origine raciale ou ethnique peuvent tous avoir un impact sur la façon dont différentes personnes répondent au même médicament ou vaccin.


En savoir plus

« Lightspeed », une méthode pour le futur de la santé ?

Pour les patients, l’industrie biopharmaceutique n’a pas d’autre choix que de passer à une autre échelle.


En savoir plus

Pfizer, une entreprise responsable engagée dans le monde entier

Découvrez les principaux engagements environnementaux et sociétaux de Pfizer


En savoir plus

Communiqués de presse

17 avril 2025Vaccination en France : le paradoxe entre reconnaissance de son importance et couverture insuffisante 03 avril 2025Pfizer lance un podcast inédit : La Fabrique de l’Innovation en Santé 21 mars 2025Prevent2Care, l’incubateur dédié à la prévention santé, lance l’appel à candidatures pour sa 7e édition

Nos aires thérapeutiques

Pour découvrir les médicaments et vaccins du futur, et adresser des pathologies pour lesquelles les besoins médicaux sont encore importants ou non couverts, Pfizer déploie son expertise et ses priorités de recherche autour de 6 aires thérapeutiques majeures.

Découvrir

Nos engagements

En tant qu’entreprise biopharmaceutique engagée, nous avons à cœur de bâtir la santé de demain avec le monde qui nous entoure, en soutenant le dynamisme de l’innovation française, en intégrant les patients au cœur de nos activités, et en adressant les enjeux sociétaux et environnementaux, de santé publique et de prévention.

Découvrir

Découvrir Pfizer

L'histoire de Pfizer commence en 1849 à New York. C'est de là que l'aventure entrepreneuriale de deux cousins fraichement arrivés d’Allemagne va prendre son essor à travers le monde et impulser des innovations marquantes au fil des siècles. Pfizer s’implante en France en 1954, devenant un pays stratégique pour l’entreprise. 

Découvrir

Nous contacter

Retrouvez les différents moyens d'entrer en contact avec nos services. Numéros de téléphone, adresses e-mail et liens utiles pour nous contacter selon votre besoin : pharmacovigilance, information médicale, lanceurs d'alerte...

En savoir plus
MédicamentsProfessionnels de santéConseils et préventionMédias Actus Aires thérapeutiquesR&DEngagementsNous connaîtreTravailler chez PfizerConditions générales d'utilisation Cookies Données personnelles ContactPP-GIP-FRA-1849
Copyright © 2022 Pfizer inc. Tous droits réservés. Le contenu de ce site est destiné aux personnes résidant en France.
Nos médicamentsEspace médiasPodcastsLa Fabrique de l'innovation en santéDécouvrir PfizerNos innovationsNotre expertiseCarrièresActualitésContactConditions générales d'utilisation Cookies Données personnelles Éthique et transparenceInformations aux patientsNos sites PfizerPP-UNP-FRA-1121
Copyright © 2025 Pfizer inc. Tous droits réservés. Le contenu de ce site est destiné aux personnes résidant en France.